|Bid||0.0000 x 800|
|Ask||0.0000 x 800|
|Day's Range||2.7600 - 2.9299|
|52 Week Range||1.3700 - 9.8000|
|Beta (5Y Monthly)||2.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
Subscribe to Yahoo Finance Plus to view Fair Value for KOD
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023, at 3:25 p.m. Eastern Time (12:25 p.m. Pacific Time).
Kodiak (KOD) reports better-than-expected third-quarter 2023 results and provides updates regarding its pipeline development plans.
Key Financial Highlights and Pipeline Developments